Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Study Provides More Treatment Options for Severe COVID-19

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis.

11 Jul 2023

Using in vivo self-assembled siRNA as part of combination therapy for ulcerative colitis

There is still a large unmet medical need for the treatment of ulcerative colitis, despite recent improvements in the understanding of the pathogenic mechanisms of ulcerative colitis.

30 Sep 2022

Study shows how innate lymphoid cells may help to treat inflammatory bowel disease

A team of researchers at Sweden’s Karolinska Institutet studied how specific immune cells known as innate lymphoid cells (ILCs), which play a role in inflammatory bowel disease (IBD), evolve into mature cells.

18 Apr 2022